-+ 0.00%
-+ 0.00%
-+ 0.00%

Medexus Management Commentary Attributes Fiscal Q2 2027 Adjusted EBITDA Growth to GRAFAPEX Operating Leverage

PUBT·11/11/2026 23:00:27
Listen to the news
Medexus Management Commentary Attributes Fiscal Q2 2027 Adjusted EBITDA Growth to GRAFAPEX Operating Leverage
  • Medexus Pharmaceuticals management commentary attributed fiscal Q2 2027 revenue growth of 17.6% to GRAFAPEX, IXINITY and Rasuvo.
  • Revenue reached USD 29.1 million, with net income of USD 813,000.
  • Adjusted EBITDA rose 16.7% to USD 5.08 million, primarily reflecting GRAFAPEX revenue exceeding commercialization investments and product costs.
  • IXINITY benefited from unusual patient demand, while generic competition affecting Rupall partially offset earnings growth.
  • Management expects GRAFAPEX revenue of USD 30 million to USD 32 million for fiscal 2027, supported by adoption and repeat orders.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medexus Pharmaceuticals Inc. published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein.